Effective and safe tumor inhibition using vinblastine in medulloblastoma.
medulloblastoma
neuropathy
subgroup
vinblastine
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
11
01
2019
revised:
07
02
2019
accepted:
15
02
2019
pubmed:
9
3
2019
medline:
21
12
2019
entrez:
9
3
2019
Statut:
ppublish
Résumé
Most medulloblastoma protocols worldwide include vincristine during radiation and chemotherapy. A significant dose-limiting toxicity is peripheral neuropathy; however, there is a paucity of data to support the view that omission of vincristine does not impact survival. Herein we report two adolescent patients with Group 4 and SHH medulloblastoma, where vinblastine successfully replaced vincristine with resolution of their peripheral neuropathy. We furthermore show vinblastine is highly active in vitro and demonstrates equivalent antitumoral activity compared to vincristine. Substitution of vincristine with vinblastine in future studies should be considered for all patients with medulloblastoma, particularly those with hereditary neuropathy, severe vincristine toxicity, and adults.
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Vinblastine
5V9KLZ54CY
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27694Subventions
Organisme : CIHR
ID : Project Grant
Pays : Canada
Informations de copyright
© 2019 Wiley Periodicals, Inc.